Review on 505(b)(2) Drug Products Approved by USFDA from 2010 to 2020 Emphasizing Intellectual Property and Regulatory Considerations for Reformulations and New Combinations
1. 系统已在2025-04-21 10:22:08对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.xphs.2023.04.004
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0022354923001508
其他信息:
出版社: Elsevier BV
作者: Jyosna Devi Ravula; Ramakrishna Nirogi; Manthan D. Janodia